217 related articles for article (PubMed ID: 20833122)
1. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines.
Feng F; Teoh CQ; Qiao Q; Boyle D; Jilbert AR
Vaccine; 2010 Oct; 28(46):7436-43. PubMed ID: 20833122
[TBL] [Abstract][Full Text] [Related]
2. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection.
Miller DS; Halpern M; Kotlarski I; Jilbert AR
Virology; 2006 May; 348(2):297-308. PubMed ID: 16469347
[TBL] [Abstract][Full Text] [Related]
4. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner.
Miller DS; Kotlarski I; Jilbert AR
Virology; 2006 Jul; 351(1):159-69. PubMed ID: 16624364
[TBL] [Abstract][Full Text] [Related]
5. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of neutralizing humoral response of DNA vaccine against duck hepatitis B virus envelope protein by co-delivery of cytokine genes.
Saade F; Buronfosse T; Pradat P; Abdul F; Cova L
Vaccine; 2008 Sep; 26(40):5159-64. PubMed ID: 18554756
[TBL] [Abstract][Full Text] [Related]
7. In vivo electroporation improves therapeutic potency of a DNA vaccine targeting hepadnaviral proteins.
Khawaja G; Buronfosse T; Jamard C; Abdul F; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans CF; Hartmann D; Cova L
Virology; 2012 Nov; 433(1):192-202. PubMed ID: 22921316
[TBL] [Abstract][Full Text] [Related]
8. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.
Foster WK; Miller DS; Scougall CA; Kotlarski I; Colonno RJ; Jilbert AR
J Virol; 2005 May; 79(9):5819-32. PubMed ID: 15827196
[TBL] [Abstract][Full Text] [Related]
9. Delipidation of a hepadnavirus: Viral inactivation and vaccine development.
Cham BE; Vickery K; Tohidi-Esfahani R; Cossart Y
J Virol Methods; 2006 Oct; 137(1):160-3. PubMed ID: 16808980
[TBL] [Abstract][Full Text] [Related]
10. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.
Foster WK; Miller DS; Marion PL; Colonno RJ; Kotlarski I; Jilbert AR
Antimicrob Agents Chemother; 2003 Aug; 47(8):2624-35. PubMed ID: 12878529
[TBL] [Abstract][Full Text] [Related]
11. Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation.
Khawaja G; Buronfosse T; Jamard C; Guerret S; Zoulim F; Luxembourg A; Hannaman D; Evans C; Hartmann D; Cova L
Virology; 2012 Mar; 425(1):61-9. PubMed ID: 22284894
[TBL] [Abstract][Full Text] [Related]
12. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
[TBL] [Abstract][Full Text] [Related]
13. DNA vaccination in combination or not with lamivudine treatment breaks humoral immune tolerance and enhances cccDNA clearance in the duck model of chronic hepatitis B virus infection.
Thermet A; Buronfosse T; Werle-Lapostolle B; Chevallier M; Pradat P; Trepo C; Zoulim F; Cova L
J Gen Virol; 2008 May; 89(Pt 5):1192-1201. PubMed ID: 18420797
[TBL] [Abstract][Full Text] [Related]
14. [Establishment of an in vivo model for duck hepatitis B virus infection using Hubei duckling].
Hu Q; Fang Y; Zhang ZM; Zhang XY; Zhang ZH; Yang DL
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Apr; 22(2):113-5. PubMed ID: 18574531
[TBL] [Abstract][Full Text] [Related]
15. Alternative methods for validation of cell culture infection with duck hepatitis B virus.
Sauerbrei A; Schacke M; Schultz U; Egerer R; Merkle I; Glebe D; Gerlich W; Wutzler P
J Virol Methods; 2005 Nov; 129(2):178-85. PubMed ID: 16002155
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks.
Jilbert AR; Miller DS; Scougall CA; Turnbull H; Burrell CJ
Virology; 1996 Dec; 226(2):338-45. PubMed ID: 8955053
[TBL] [Abstract][Full Text] [Related]
17. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
Reaiche GY; Le Mire MF; Mason WS; Jilbert AR
Virology; 2010 Oct; 406(2):286-92. PubMed ID: 20705309
[TBL] [Abstract][Full Text] [Related]
18. Progress in DNA vaccine for prophylaxis and therapy of hepatitis B.
Thermet A; Rollier C; Zoulim F; Trepo C; Cova L
Vaccine; 2003 Jan; 21(7-8):659-62. PubMed ID: 12531335
[TBL] [Abstract][Full Text] [Related]
19. Contribution of aflatoxin B1 and hepatitis B virus infection in the induction of liver tumors in ducks.
Cova L; Wild CP; Mehrotra R; Turusov V; Shirai T; Lambert V; Jacquet C; Tomatis L; Trépo C; Montesano R
Cancer Res; 1990 Apr; 50(7):2156-63. PubMed ID: 2107970
[TBL] [Abstract][Full Text] [Related]
20. Viral load in 1-day-old ducklings acutely infected with duck hepatitis B virus by different doses and routes of inoculation.
Chen ZY; Cheng AC; Wang MS; Xu DW; Jia R; Guo YF; Zeng W
Avian Pathol; 2009 Apr; 38(2):129-34. PubMed ID: 19322711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]